Adult Patient with Pseudo-Resistant Hypertension: Drug Intolerance
Despite the increasing evidence of the severe consequences of uncontrolled blood pressure, in a large proportion of patients, BP targets are not achieved. Today, several classes of effective antihypertensive drugs are available, and in particular ACE inhibitors, angiotensin II receptor blockers, calcium antagonists, diuretics and beta blockers are all considered first-line drugs by current European Guidelines; furthermore, other molecules may be added as needed. However, in everyday practice clinicians may face with some problems related to drug treatment. In fact, in some patients, the number of drugs available for the treatment of hypertension is limited. This clinical case describes the eventuality in which patients are intolerant to more than one antihypertensive drug class. In patients with difficult-to-treat hypertension, this may represent a serious barrier to BP control. In the case described here, blood pressure control was obtained combining a renin angiotensin system blocker with a thiazide-like diuretic and a mineralocorticoid receptor antagonist. Antialdosterone drugs are not among the recommended first-line drugs for hypertension but, as also indicated by the ESH ESC Hypertension Guidelines, can be used as a third- or fourth-line drugs, being among the most effective additional antihypertensive drugs.
KeywordsCalcium Antagonist Ambulatory Blood Pressure Monitoring Fixed Combination Mineralocorticoid Receptor Antagonist Blood Pressure Profile
- 1.Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P, European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106(19):2422–7.CrossRefPubMedGoogle Scholar
- 2.Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.CrossRefPubMedGoogle Scholar
- 5.Chapman N, Chang CL, Dahlöf B, Sever PS, Wedel H, Poulter NR, ASCOT Investigators. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118(1):42–8.CrossRefPubMedGoogle Scholar
- 7.Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68.CrossRefPubMedPubMedCentralGoogle Scholar